WEST PHARMACEUTICAL SERVICES, INC. Operating Lease Cost
WEST PHARMACEUTICAL SERVICES, INC. (WST) reported Operating Lease Cost of $7.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-07-23
- WEST PHARMACEUTICAL SERVICES, INC. operating lease, cost for the quarter ending 2026-06-30 was $7.30M, a 7.35% increase year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. operating lease, cost for the quarter ending 2026-03-31 was $7.20M, a 9.09% increase year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. operating lease, cost for the quarter ending 2025-12-31 was $6.20M, a 1.64% increase year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. operating lease, cost for the quarter ending 2025-09-30 was $6.90M, a 7.81% increase year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. operating lease, cost for fiscal 2025 was $26.50M, a 9.50% increase from fiscal 2024.
- WEST PHARMACEUTICAL SERVICES, INC. operating lease, cost for fiscal 2024 was $24.20M, a 19.21% increase from fiscal 2023.
- WEST PHARMACEUTICAL SERVICES, INC. operating lease, cost for fiscal 2023 was $20.30M, a 30.97% increase from fiscal 2022.
- WEST PHARMACEUTICAL SERVICES, INC. operating lease, cost for fiscal 2022 was $15.50M, a 22.05% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.30M 10-Q · filed 2026-07-23 | $14.50M 10-Q · filed 2026-07-23 | $20.70M derived: sum of 3 quarters · filed 2026-07-23 | $27.60M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $7.20M 10-Q · filed 2026-04-23 | $13.40M derived: sum of 2 quarters · filed 2026-04-23 | $20.30M derived: sum of 3 quarters · filed 2026-04-23 | $27.10M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $13.10M derived: sum of 2 quarters · filed 2026-02-17 | $19.90M derived: sum of 3 quarters · filed 2026-07-23 | $26.50M 10-K · filed 2026-02-17 |
| 2025-09-30 | $6.90M 10-Q · filed 2025-10-23 | $13.70M derived: sum of 2 quarters · filed 2026-07-23 | $20.30M 10-Q · filed 2025-10-23 | $26.40M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $6.80M 10-Q · filed 2026-07-23 | $13.40M 10-Q · filed 2026-07-23 | $19.50M derived: sum of 3 quarters · filed 2026-07-23 | $25.90M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $6.60M 10-Q · filed 2026-04-23 | $12.70M derived: sum of 2 quarters · filed 2026-04-23 | $19.10M derived: sum of 3 quarters · filed 2026-04-23 | $25.20M derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $6.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $12.50M derived: sum of 2 quarters · filed 2026-02-17 | $18.60M derived: sum of 3 quarters · filed 2026-02-17 | $24.20M 10-K · filed 2026-02-17 |
| 2024-09-30 | $6.40M 10-Q · filed 2025-10-23 | $12.50M derived: sum of 2 quarters · filed 2025-10-23 | $18.10M 10-Q · filed 2025-10-23 | $23.40M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $6.10M 10-Q · filed 2025-07-24 | $11.70M 10-Q · filed 2025-07-24 | $17.00M derived: sum of 3 quarters · filed 2026-02-17 | $21.30M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $5.60M 10-Q · filed 2025-04-24 | $10.90M derived: sum of 2 quarters · filed 2026-02-17 | $15.20M derived: sum of 3 quarters · filed 2026-02-17 | $20.00M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $9.60M derived: sum of 2 quarters · filed 2026-02-17 | $14.40M derived: sum of 3 quarters · filed 2026-02-17 | $20.30M 10-K · filed 2026-02-17 |
| 2023-09-30 | $4.30M 10-Q · filed 2024-10-24 | $9.10M derived: sum of 2 quarters · filed 2024-10-24 | $15.00M 10-Q · filed 2024-10-24 | $20.10M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $4.80M 10-Q · filed 2024-07-25 | $10.70M 10-Q · filed 2024-07-25 | $15.80M derived: sum of 3 quarters · filed 2025-02-18 | $19.50M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $5.90M 10-Q · filed 2024-04-25 | $11.00M derived: sum of 2 quarters · filed 2025-02-18 | $14.70M derived: sum of 3 quarters · filed 2025-02-18 | $18.10M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $8.80M derived: sum of 2 quarters · filed 2025-02-18 | $12.20M derived: sum of 3 quarters · filed 2025-02-18 | $15.50M 10-K · filed 2025-02-18 |
| 2022-09-30 | $3.70M 10-Q · filed 2023-10-26 | $7.10M derived: sum of 2 quarters · filed 2023-10-26 | $10.40M 10-Q · filed 2023-10-26 | $13.60M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $3.40M 10-Q · filed 2023-07-27 | $6.70M 10-Q · filed 2023-07-27 | $9.90M derived: sum of 3 quarters · filed 2024-02-20 | $13.20M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $3.30M 10-Q · filed 2023-04-27 | $6.50M derived: sum of 2 quarters · filed 2024-02-20 | $9.80M derived: sum of 3 quarters · filed 2024-02-20 | $12.90M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $6.50M derived: sum of 2 quarters · filed 2024-02-20 | $9.60M derived: sum of 3 quarters · filed 2024-02-20 | $12.70M 10-K · filed 2024-02-20 |
| 2021-09-30 | $3.30M 10-Q · filed 2022-10-27 | $6.40M derived: sum of 2 quarters · filed 2022-10-27 | $9.50M 10-Q · filed 2022-10-27 | $13.00M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $3.10M 10-Q · filed 2022-07-28 | $6.20M 10-Q · filed 2022-07-28 | $9.70M derived: sum of 3 quarters · filed 2023-02-21 | $12.80M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $3.10M 10-Q · filed 2022-04-28 | $6.60M derived: sum of 2 quarters · filed 2023-02-21 | $9.70M derived: sum of 3 quarters · filed 2023-02-21 | $12.80M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $6.60M derived: sum of 2 quarters · filed 2023-02-21 | $9.70M derived: sum of 3 quarters · filed 2023-02-21 | $12.80M 10-K · filed 2023-02-21 |
| 2020-09-30 | $3.10M 10-Q · filed 2021-10-28 | $6.20M derived: sum of 2 quarters · filed 2021-10-28 | $9.30M 10-Q · filed 2021-10-28 | $12.50M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $3.10M 10-Q · filed 2021-07-30 | $6.20M 10-Q · filed 2021-07-30 | $9.40M derived: sum of 3 quarters · filed 2022-02-22 | $12.80M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $3.10M 10-Q · filed 2021-04-30 | $6.30M derived: sum of 2 quarters · filed 2022-02-22 | $9.70M derived: sum of 3 quarters · filed 2022-02-22 | $12.80M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $6.60M derived: sum of 2 quarters · filed 2022-02-22 | $9.70M derived: sum of 3 quarters · filed 2022-02-22 | $12.90M 10-K · filed 2022-02-22 |
| 2019-09-30 | $3.40M 10-Q · filed 2020-10-23 | $6.50M derived: sum of 2 quarters · filed 2020-10-23 | $9.70M 10-Q · filed 2020-10-23 | |
| 2019-06-30 | $3.10M 10-Q · filed 2020-07-24 | $6.30M 10-Q · filed 2020-07-24 | ||
| 2019-03-31 | $3.20M 10-Q · filed 2020-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |